Drugging the undruggable – the story of Ras
Drug discovery and development are lengthy processes for even the most established Healthcare companies. Despite advancements in technology and ever more accessible research, commercialising new therapeutics still requires a significant amount of time and capital. Given these caveats, Healthcare companies dedicate significant resources to identify high potential drug targets within the cell. However, certain biomolecular components have proved challenging to build robust therapeutics for. Here, we explore why the Ras family of proteins are such attractive drug targets and why some Healthcare companies still have skin in the game despite four decades of failed attempts.
Arjun Kandola
December 13, 2024